An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of Olinciguat (IW-1701)

To evaluate the effect of itraconazole (a potent cytochrome P450 isoenzyme [CYP]3A inhibitor) on the pharmacokinetics (PK) of olinciguat

Start Date03 May 2019

Sponsor / Collaborator

Cyclerion Therapeutics

NCT03795519 / CompletedPhase 1

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Olinciguat ([14C]-IW-1701) Following a Single Oral Dose in Healthy Male Subjects

The primary objective is to characterize the pharmacokinetics (PK) of olinciguat and total radioactivity and to assess the elimination of total radioactivity from a single oral dose of [14C]-olinciguat.

Start Date17 Jan 2019

Sponsor / Collaborator

Cyclerion Therapeutics

NCT03285178 / CompletedPhase 2

A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease

The primary objective of the 1701-202 STRONG SCD study is to evaluate the safety and tolerability of different dose levels of IW-1701 compared with placebo when administered daily for approximately 12 weeks to patients with stable SCD. Exploratory objectives include evaluation of pharmacokinetic (PK) as well as evaluation of the effect of IW-1701 on symptoms of SCD, health-related quality of life, and biomarkers of pharmacodynamic (PD) activity.

Start Date22 Dec 2017

Sponsor / Collaborator

Cyclerion Therapeutics

100 Clinical Results associated with Olinciguat

100 Translational Medicine associated with Olinciguat

100 Patents (Medical) associated with Olinciguat

Literatures (Medical) associated with Olinciguat

01 Sep 2021·British journal of pharmacology

Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso‐occlusion and nephropathy in mouse models of sickle cell disease

Article

Author: Gao, Xin ; Tchernychev, Boris ; Feil, Susanne ; Feil, Robert ; Frenette, Paul S. ; Masferrer, Jaime L. ; Li, Huihui ; Buys, Emmanuel S. ; Hall, Katherine C. ; Ramanarasimhaiah, Raghunath ; Graul, Regina M. ; Jones, Juli E. ; Liu, Guang ; Bernier, Sylvie G. ; Lee, Sung‐Kyun

Background and Purpose:

Reduced bioavailability of NO, a hallmark of sickle cell disease (SCD), contributes to intravascular inflammation, vasoconstriction, vaso‐occlusion and organ damage observed in SCD patients. Soluble guanylyl cyclase (sGC) catalyses synthesis of cGMP in response to NO. cGMP‐amplifying agents, including NO donors and phosphodiesterase 9 inhibitors, alleviate TNFα‐induced inflammation in wild‐type C57BL/6 mice and in ‘humanised’ mouse models of SCD.

Experimental Approach:

Effects of the sGC stimulator olinciguat on intravascular inflammation and renal injury were studied in acute (C57BL6 and Berkeley mice) and chronic (Townes mice) mouse models of TNFα‐induced and systemic inflammation associated with SCD.

Key Results:

Acute treatment with olinciguat attenuated increases in plasma biomarkers of endothelial cell activation and leukocyte‐endothelial cell interactions in TNFα‐challenged mice. Co‐treatment with hydroxyurea, an FDA‐approved SCD therapeutic agent, further augmented the anti‐inflammatory effect of olinciguat. In the Berkeley mouse model of TNFα‐induced vaso‐occlusive crisis, a single dose of olinciguat attenuated leukocyte‐endothelial cell interactions, improved blood flow and prolonged survival time compared to vehicle‐treated mice. In Townes SCD mice, plasma biomarkers of inflammation and endothelial cell activation were lower in olinciguat‐ than in vehicle‐treated mice. In addition, kidney mass, water consumption, 24‐h urine excretion, plasma levels of cystatin C and urinary excretion of N‐acetyl‐β‐d‐glucosaminidase and neutrophil gelatinase‐associated lipocalin were lower in Townes mice treated with olinciguat than in vehicle‐treated mice.

Conclusion and Implications:

Our results suggest that the sGC stimulator olinciguat attenuates inflammation, vaso‐occlusion and kidney injury in mouse models of SCD and systemic inflammation.

Frontiers in pharmacologyQ2 · MEDICINE

Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease

Q2 · MEDICINE

ArticleOA

Author: Milne, G Todd ; Chickering, Jennifer G ; Price, Gavrielle M ; Sarno, Renee ; Jones, Juli E ; Buys, Emmanuel S ; Bernier, Sylvie G ; Sykes, Kristie ; Wakefield, James D ; Tobin, Jenny V ; Germano, Peter ; Chien, Yueh-Tyng ; Zimmer, Daniel P ; Graul, Regina ; Currie, Mark G ; Masferrer, Jaime L ; Carvalho, Andrew ; Jacobson, Sarah ; Banijamali, Ali R ; Shea, Courtney M ; Tchernychev, Boris

Nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic 3',5' GMP (cGMP) signaling plays a central role in regulation of diverse processes including smooth muscle relaxation, inflammation, and fibrosis. sGC is activated by the short-lived physiologic mediator NO. sGC stimulators are small-molecule compounds that directly bind to sGC to enhance NO-mediated cGMP signaling. Olinciguat, (R)-3,3,3-trifluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)-2-hydroxypropanamide, is a new sGC stimulator currently in Phase 2 clinical development. To understand the potential clinical utility of olinciguat, we studied its pharmacokinetics, tissue distribution, and pharmacologic effects in preclinical models. Olinciguat relaxed human vascular smooth muscle and was a potent inhibitor of vascular smooth muscle proliferation in vitro. These antiproliferative effects were potentiated by the phosphodiesterase 5 inhibitor tadalafil, which did not inhibit vascular smooth muscle proliferation on its own. Olinciguat was orally bioavailable and predominantly cleared by the liver in rats. In a rat whole body autoradiography study, olinciguat-derived radioactivity in most tissues was comparable to plasma levels, indicating a balanced distribution between vascular and extravascular compartments. Olinciguat was explored in rodent models to study its effects on the vasculature, the heart, the kidneys, metabolism, and inflammation. Olinciguat reduced blood pressure in normotensive and hypertensive rats. Olinciguat was cardioprotective in the Dahl rat salt-sensitive hypertensive heart failure model. In the rat ZSF1 model of diabetic nephropathy and metabolic syndrome, olinciguat was renoprotective and associated with lower circulating glucose, cholesterol, and triglycerides. In a mouse TNFα-induced inflammation model, olinciguat treatment was associated with lower levels of endothelial and leukocyte-derived soluble adhesion molecules. The pharmacological features of olinciguat suggest that it may have broad therapeutic potential and that it may be suited for diseases that have both vascular and extravascular pathologies.

News (Medical) associated with Olinciguat

08 Dec 2023

·www.fiercebiotech.com

Chutes & Ladders—BIO lands rare disease advocate John Crowley as CEO

None Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week. BIO lands rare disease advocate John Crowley as CEO Biotechnology Innovation Organization For more than a year, the Biotechnology Innovation Organization (BIO) has been led by interim CEO Rachel King. Now, the organization has named a permanent successor. Rare disease advocate, biotech founder and BIO board member John Crowley is set to take the top spot starting March 4. Crowley is probably best known for his entrepreneurship in the industry after his two youngest children were diagnosed with Pompe disease, a rare genetic neuromuscular disorder. He co-founded Novazyme Pharmaceuticals (acquired by Genzyme) and served as a founding leader for Orexigen Therapeutics and Amicus Therapeutics, where he served as CEO from 2005-2022. Crowley currently serves as Amicus’ executive chair and will stay in that role until March. The military veteran’s search for a Pompe disease treatment was documented in the 2010 movie Extraordinary Measures, directed by Harrison Ford. Crowley will take the reins of the advocacy organization as the industry continues to brace itself against potential implications of the IRA and challenging market conditions. Release Cyclerion Therapeutics picks former EQRx leader as new CEO Cyclerion Therapeutics Regina Graul, Ph.D., has found a new role at the top of Cyclerion Therapeutics, replacing outgoing founding CEO Peter Hecht, Ph.D. It’s a return to home for the executive, who previously led development of Cylcerion’s olinciguat program for cardiovascular disease. Graul comes from EQRx, a biotech that had attempted to make low-cost oncology drugs but ultimately shut down earlier this year. There, Graul served as a program executive overseeing cross-functional development teams in oncology. Graul will have a challenging job in front of her. Cyclerion has been through a tough few years, shifting clinical plans twice in 2022. “As we evaluate our existing assets and identify external value-creating opportunities, cutting-edge innovation and addressing unmet patient needs will be central tenets,” Graul said in a statement. The new CEO is effective immediately. However, Hecht will continue as a strategic consultant and board director. Release Sensorium selects new CEO Sensorium Therapeutics Psychoactive medicine-focused Sensorium has selected Alexandra (Sandra) Glucksmann, Ph.D., to helm the biotech as former CEO and co-founder Dick Simon transitions to an advisory role. Simon held the role since helping launch the nature-inspired platform company in 2021. New CEO Glucksmann has more than 30 years of industry experience, most recently serving as founding CEO and president of oncology company Cedilla Therapeutics. She also served as the founding chief operating officer for gene editing company Editas Medicine and currently holds board spots at REGENXBIO and Scenic Biotech. Release > Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. Elizabeth Mily, who replaced BMS’ former M&A czar Paul Biondi back in 2020, is headed for the exit after joining the pharma company in spring of 2020 from Barclays. Her departure has prompted BMS to launch a search for a replacement, with the company's spokesperson noting that "strategy and business development is critical to our business strategy." Fierce Pharma > Bob Smith has left Merck & Co. for Gossamer Bio, where he will serve as chief commercial officer. Smith most recently led Merck’s sotatercept pre-launch activities in the U.S. as the national sales lead, and previously led U.S. sales operations for Actelion. Release > Ophthalmic biotech SpyGlass Pharma has selected Margot Goodkin, M.D., Ph.D., to serve as chief medical officer. Before SpyGlass, Goodkin was executive director of ophthalmology clinical development at Allergan/AbbVie and also previously worked at the FDA’s Center for Devices and Radiologic Health. Release > Kling Bio has tapped Stefano Gullà, Ph.D., to serve as chief scientific officer. Before joining Kling, Gullà has held senior roles at Pfizer, Agenus, Flagship and RVAC. Release > As part of a layoff round, Theseus Pharmaceuticals has sent CEO and President Timothy Clackson, Ph.D., and Chief Medical Officer David Kerstein, M.D., packing. Release > Zenas BioPharma is welcoming Jennifer Fox on as chief business officer and chief financial officer, as well as Tanya Fischer, M.D., Ph.D., as head of R&D and chief medical officer. Before Zenas, Fox served as Nuvation Bio’s chief financial officer, while Fischer served as Biohaven’s chief development officer and head of translational medicine. Release > Catalyst Pharmaceuticals has appointed Michael Kalb—who most recently served Impel Pharmaceutical’s chief financial officer, as its EVP and CFO—as current CFO Alicia Grande retires at the end of the year after a 16-year tenure with the company. Catalyst is also promoting Steven Miller, Ph.D., to EVP, chief operating and scientific officer, while Jeffrey Del Carmen has been promoted to EVP and chief commercial officer. Release > Alentis Therapeutics has appointed Rizwan Velji to serve as chief business officer. He joins the Swiss biotech from William Blair, where he most recently served as managing director. Release > While Hepion Pharmaceuticals’ board has approved a plan designed to slash operating costs by 60%, CEO Robert Foster, Ph.D., has resigned, citing personal reasons. Chief Financial Officer John Cavan has stepped up and will lead the biotech as interim CEO. Fierce Biotech > ARTBIO has closed a $90 million series A round and hired a handful of new executives. Philippe Dasse, Ph.D., previously head of technical operations for radioligand therapies at Novartis, will be the chief technical officer, while Daniel Rossett will be SVP and head of supply chain and external manufacturing. Rossett was global head of supply chain at Novartis’ radiopharma unit, Advanced Accelerator Applications. Fierce Biotech > Empress Therapeutics has chosen Virginia Finnerty-Brooks to serve as the biotech’s chief business officer. Finnerty-Brooks holds more than 25 years of industry experience, holding roles across Adanate, Eli Lilly’s Dermira, DSM Biomedical, Cellastra, Precigen, FibroGen and EPL Technologies. Release

Executive Change

04 Dec 2023

·www.biospace.com

Cyclerion Appoints Regina Graul, Ph.D., as President

– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion’s president, she will lead the organization and will work closely with, and report directly to, the board of directors. She will be responsible for creating, implementing, and executing strategy as well as building a uniquely talented cross-functional management team. With Graul’s arrival, transitional commitments under the asset purchase agreement with Tisento Therapeutics completed, and general expense reductions largely in place, founding chief executive officer Peter Hecht, Ph.D. has completed his transitional assignment. As a result, he is stepping away from an operational role at Cyclerion, effective immediately, and will continue to work with Dr. Graul and her team as a strategic consultant and board director going forward. “I am thrilled to be joining Cyclerion at this pivotal moment. The recent additions of Dina Katabi and Michael Higgins as board members and the evolution of Cyclerion’s board and management team provide a key inflection point to re-envision the company’s future,” said Dr. Graul. “As we evaluate our existing assets and identify external value-creating opportunities, cutting-edge innovation and addressing unmet patient needs will be central tenets. Together with our outstanding board of directors, I look forward to building Cyclerion’s capabilities for its next chapter to bring meaningful medicines to the patients who need them most.” “I am optimistic about the future of Cyclerion with Regina shepherding the company, a top-notch board of directors, promising existing assets, and a strategy for growth and evolution through external innovation,” said Dr. Hecht. “Having worked with Regina personally for years at Microbia, Ironwood, and Cyclerion, I can attest to her effective leadership style, savvy sense of strategy, and ability to identify and advance promising science. I look forward to working with her and the rest of the board as we build the next phase of the company and seek to make important progress on behalf of patients.” Regina most recently served as vice president, program executive at EQRx, where she led cross-functional development teams in oncology, using the latest in clinical innovation to create and deliver sustainable solutions. Previously, she served as olinciguat program lead at Cyclerion where she oversaw all aspects of olinciguat research and development. She began her industry career at Ironwood Pharmaceuticals (formerly Microbia Inc.) after completing a postdoctorate at MIT. She received her Ph.D. in synthetic organic chemistry from Rice University and her B.A. in chemistry from Saint Anselm College. About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion acquired 10 percent equity ownership in Tisento Therapeutics as part of an asset sale agreement in which Tisento acquired the brain-penetrant soluble guanylate cyclase (sGC) stimulators zagociguat and CY3018 acquired from Cyclerion. Cyclerion’s current portfolio includes novel sGC stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia. Olinciguat is a vascular sGC stimulator that Cyclerion intends to out-license for cardiovascular diseases. Concurrently, Cyclerion is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. Forward Looking Statement Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should”, “positive”, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about pursuing collaborations, licenses, mergers, acquisitions and/or other targeted investments aimed at enhancing shareholder value. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, those under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 22, 2023 and in our Form 10-Q filed with the SEC on July 28, 2023, as well as our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Contacts Investor & Media Relations Phone: 857-327-8778 Email: IR@cyclerion.com

Executive ChangeAcquisition

30 Nov 2023

·www.globenewswire.com

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced the appointments of Dina Katabi, Ph.D., and Michael Higgins to its Board of Directors. “Dina and Michael bring a unique combination of leadership capabilities, operating experience, and vast cutting-edge scientific knowledge. Having a world-renowned innovator and a biopharma veteran join the board facilitates the transformation of Cyclerion as we look ahead to possible licenses, mergers, acquisitions and/or other targeted investments,” said Errol DeSouza, Ph.D., chairperson of Cyclerion Therapeutics. Dina Katabi, Ph.D., is the Thuan and Nicole Pham Professor of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology (MIT), the director of MIT’s Center for Wireless Networks and Mobile Computing, and a member of the National Academy of Engineering, the National Academy of Sciences, and the American Academy of Arts and Sciences. She is also a recipient of the MacArthur Genius Award. Her research focuses on digital health, machine learning, and wireless and mobile technologies. Several start-ups have been spun out of Dr. Katabi's lab. She is the co-founder and president of Emerald Innovations, a health analytics company that specializes in digital health solutions for passive, contactless, in-home monitoring. She received her Ph.D. and M.S. in Computer Science from MIT and her B.S. from Damascus University. Michael Higgins is a serial entrepreneur who has helped launch and build numerous companies during his 30+ year career. Michael served as Voyager Therapeutics’ Interim Chief Executive Officer from June 2021 to March 2022. In this role he was able to stabilize and relaunch the company through the completion of three major business development deals, and the restructuring of the management team and research portfolio. Mr. Higgins was an entrepreneur-in-residence at Polaris Partners from 2015 to 2020 where he helped the founding team launch Camp4 Therapeutics. From 2003 through 2014 he served as Senior Vice President, Chief Operating Officer at Ironwood Pharmaceuticals Inc., evolving the company from its early days as a venture backed start-up to a fully integrated commercial organization. Mr. Higgins has been a long-time board member and board chair at other public and private companies. He is currently Chairman of the Board of Voyager Therapeutics as well as Pulmatrix Therapeutics. He also served as Audit Committee Chair at Voyager and has extensive compensation committee and governance committee experience. His financial expertise ranges from seed stage financing to IPOs, and beyond. He earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College. About Cyclerion TherapeuticsCyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion acquired 10 percent equity ownership in Tisento Therapeutics as part of an asset sale agreement in which Tisento acquired the brain-penetrant soluble guanylate cyclase (sGC) stimulators zagociguat and CY3018 acquired from Cyclerion. Cyclerion’s current portfolio includes novel sGC stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that Cyclerion intends to out-license for cardiovascular diseases. Concurrently, Cyclerion is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. Forward Looking StatementCertain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should”, “positive”, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about pursuing collaborations, licenses, mergers, acquisitions and/or other targeted investments aimed at enhancing shareholder value. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, those under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 22, 2023 and in our Form 10-Q filed with the SEC on July 28, 2023, as well as our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. ContactsInvestor & Media RelationsPhone: 857-327-8778Email: IR@cyclerion.com

Executive ChangeAcquisition

100 Deals associated with Olinciguat

External Link

KEGG	Wiki	ATC	Drug Bank
D11475	-	-	DB15238

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia, Sickle Cell	Phase 2	US	Cyclerion Therapeutics	22 Dec 2017
Anemia, Sickle Cell	Phase 2	LB	Cyclerion Therapeutics	22 Dec 2017
Anemia, Sickle Cell	Phase 2	GB	Cyclerion Therapeutics	22 Dec 2017
Esophageal Achalasia	Phase 2	US	Cyclerion Therapeutics	06 Apr 2017
Gastrointestinal Diseases	Phase 2	US	Ironwood Pharmaceuticals, Inc.	-
Cardiovascular Diseases	Phase 1	-	Ironwood Pharmaceuticals, Inc.	-
Fibrosis	Phase 1	-	Ironwood Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02931565 (CTgov)	Phase 2	Esophageal Achalasia	9	Matching Placebo	pimohdbuck(crwxhkynkf) = usuelsibdu ltdelsozhu (didhrtexqm, aravcbmzjr - fnrghchxpn) View more	-	04 May 2021
ZSF1 (ASN2016)	Not Applicable	Diabetic Nephropathies reactive oxygen species \| nitric oxide	8	Enalapril	vdsnylrujf(sgiioixweu) = yqwxnviyyp mocosjeqya (mcvoaoozcj, 1)	Positive	15 Nov 2016
ZSF1 (ASN2016)	Not Applicable		8	Enalapril + IW-1701 10 mg/kg/d	vdsnylrujf(sgiioixweu) = akfteofuku mocosjeqya (mcvoaoozcj, 1)	Positive	15 Nov 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis